Success Metrics

Clinical Success Rate
40.0%

Based on 2 completed trials

Completion Rate
40%(2/5)
Active Trials
3(38%)
Results Posted
100%(2 trials)
Terminated
3(38%)

Phase Distribution

Ph phase_2
7
88%
Ph phase_1
1
13%

Phase Distribution

1

Early Stage

7

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
1(12.5%)
Phase 2Efficacy & side effects
7(87.5%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

40.0%

2 of 5 finished

Non-Completion Rate

60.0%

3 ended early

Currently Active

3

trials recruiting

Total Trials

8

all time

Status Distribution
Active(3)
Completed(2)
Terminated(3)

Detailed Status

Terminated3
Completed2
Active, not recruiting2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
3
Success Rate
40.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (12.5%)
Phase 27 (87.5%)

Trials by Status

completed225%
recruiting113%
terminated338%
active_not_recruiting225%

Recent Activity

3 active trials
Showing 5 of 8
completedphase_2

A Study of TCD601 in de Novo Renal Transplant Recipients

NCT05669001
recruitingphase_1

A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients

NCT06453668
terminatedphase_2

A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation

NCT06365437
active_not_recruitingphase_2

A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE)

NCT04803058
terminatedphase_2

A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PANORAMA)

NCT04803006
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT05669001Phase 2

A Study of TCD601 in de Novo Renal Transplant Recipients

Completed
NCT06453668Phase 1

A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients

Recruiting
NCT06365437Phase 2

A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation

Terminated
NCT04803058Phase 2

A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE)

Active Not Recruiting
NCT04803006Phase 2

A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PANORAMA)

Terminated
NCT06025110Phase 2

A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients

Terminated
NCT04311632Phase 2

A Dose Escalation Study in de Novo Renal Transplantation

Completed
NCT06019507Phase 2

A Study of TCD601 in the Induction of Tolerance in de Novo Liver Transplantation

Active Not Recruiting

All 8 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
8